Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress

Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress

2024.01.03
Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress Dr. Lai Wei is a Professor of Hepatology & Medicine, and is the Director of the Hepatobiliary and Pancreatic Center at Beijing Tsinghua Changgung Hospital. His current research interests involve antiviral treatment of hepatitis B and C. Dr. Wei is the President of the Chinese Society of Hepatology. He served to develop the Chinese Guideline for Management of Hepatitis B, and Management, Diagnosis and Prevention of Hepatitis C virus Infection. In addition, Dr Wei is involved in Kidney Disease Improving Global Outcome to develop a Guideline for HCV Infection, Diagnosis, Prevention and Management in Kidney Disease and contributes to APASL for hepatitis C guideline.
Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

2024.01.03
Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are both significant contributors to liver-related complications and mortality. Dr. Youwen Tan's team at the Third People's Hospital of Jiangsu University conducted research on the impact of NAFLD, as confirmed by liver histopathology, and pathological changes on individuals with chronic HBV infection. The latest research findings were selected for presentation at the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023
Doctor Thomas Reiberger: Hotly Debated Issues on the Use of Non-Selective Beta-Blockers (NSBBs) in the Treatment of Cirrhosis

Doctor Thomas Reiberger: Hotly Debated Issues on the Use of Non-Selective Beta-Blockers (NSBBs) in the Treatment of Cirrhosis

2023.12.21
🔍 Exploring the Complexities of Cirrhosis Treatment: Insights from Dr. Thomas Reiberger Welcome to the latest feature from Hepatology Digest, where we delve into the nuanced world of liver health. In our upcoming article, we're excited to present the esteemed Dr. Thomas Reiberger, a leading figure in hepatology, known for his extensive research and clinical expertise. Dr. Reiberger brings a wealth of knowledge to the table, particularly in the controversial use of Non-Selective Beta-Blockers (NSBBs) for treating cirrhosis. Join us as we navigate the complexities of this treatment, examining its benefits, challenges, and the heated debates it sparks in the medical community. Stay tuned for an enlightening journey through the lens of a distinguished expert. 🔗 Stay connected with Hepatology Digest for cutting-edge insights and discussions.